Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1186/bcr2479.

Title:
Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment | Breast Cancer Research
Description:
Introduction Recent data indicate a hierarchical organization of many solid cancers, including breast cancer, with a small number of cancer initiating cells (CICs) that have the ability to self-renew and exhibit multi-lineage potency. We, and others, have demonstrated that CICs in breast cancer and glioma are relatively resistant to ionizing radiation if compared to their non-tumorigenic counterparts. However, the extent of the remaining self-renewing capacity of CICs after fractions of radiation is currently unknown. We hypothesized that CICs, in contrast to their non-tumorigenic counterparts, not only survive fractions of ionizing radiation but also retain the CIC phenotype as defined by operational means. Methods We used two marker systems to identify breast CICs (CD24-/low/CD44high, or lack of proteasome activity) and performed sphere-forming assays after multiple clinical fractions of radiation. Lineage tracking was performed by membrane staining. Cell cycle distribution and RNA content were assessed by flow cytometry and senescence was assessed via Ξ²-galactosidase staining. Results We demonstrated that irradiated CICs survived and retained their self-renewal capacity for at least four generations. We show that fractionated radiation not only spared CICs but also mobilized them from a quiescent/G0 phase of the cell cycle into actively cycling cells, while the surviving non-tumorigenic cells were driven into senescence. Conclusions The breast CIC population retains increased self-renewal capacity over several generations and therefore, we conclude that increases in the number of CICs after sublethal doses of radiation have potential clinical importance. Prevention of this process may lead to improved clinical outcome.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {πŸ“š}

  • Science
  • Health & Fitness
  • Telecommunications

Content Management System {πŸ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {πŸ“ˆ}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {πŸ’Έ}

We can't tell how the site generates income.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {πŸ”}

cells, cics, radiation, cell, figure, population, fractionated, cancer, breast, nontumorigenic, mcf, zsgreencodc, capacity, dose, increase, pubmed, article, bars, phase, number, cycle, stem, sphere, staining, google, scholar, cas, treatment, fractions, senescence, selfrenewal, file, effect, activity, irradiated, control, analyzed, red, nature, authors, analysis, increased, irradiation, proliferation, fluorescence, divisions, total, cdlowcdhigh, proteasome, performed,

Topics {βœ’οΈ}

1 mg/ml 5-bromo-4-chloro-3-inolyl-Ξ²-d-galactoside anti-cd44 apc-conjugated antibody anti-cd24 pe-conjugated antibody human colon-cancer-initiating cells pheno-red free dmem-f12 cd24-/low/cd44high cell population article download pdf confluent mcf-7-zsgreen-codc monolayer mcf-7 cd24-/low/cd44high cells cd24-/low/cd44high cics markers related subjects x-gal-positive/senescent cells fluorescence-activated cell-sorting nih-gov/ij/] darzynkiewicz cell-type specific behaviour salt-free staining vehicle cellular oncology cd24-/low/cd44high cells cell line continued primary sphere-forming capacity cd24-/low/cd44high population exhibit multi-lineage potency cancer stem cell Ξ²-galactosidase-positive cells including breast cancer zsgreen-codc+ cells constituted mcf-7 cell line breast cancer cell heterogeneous monolayer population sphere-forming capacity assays zsgreen-codc-positive cells fl-1h channel exceeded t47d secondary sphere-formation cell stem cell cancer stem cells performed sphere-forming assays zsgreen-codc+ cells increased low proteasome activity cics zsgreen-codc+ showed natl cancer inst breast cancer cells cancer initiating cells stem cell properties breast cancer res measure zsgreen-codc expression 20 mg/ml stock indicating radiation-induced mobilization tumorigenic zsgreen-codc- cells cd24-/low/cd44high Ξ²-galactosidase activity

Schema {πŸ—ΊοΈ}

WebPage:
      mainEntity:
         headline:Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment
         description:Recent data indicate a hierarchical organization of many solid cancers, including breast cancer, with a small number of cancer initiating cells (CICs) that have the ability to self-renew and exhibit multi-lineage potency. We, and others, have demonstrated that CICs in breast cancer and glioma are relatively resistant to ionizing radiation if compared to their non-tumorigenic counterparts. However, the extent of the remaining self-renewing capacity of CICs after fractions of radiation is currently unknown. We hypothesized that CICs, in contrast to their non-tumorigenic counterparts, not only survive fractions of ionizing radiation but also retain the CIC phenotype as defined by operational means. We used two marker systems to identify breast CICs (CD24-/low/CD44high, or lack of proteasome activity) and performed sphere-forming assays after multiple clinical fractions of radiation. Lineage tracking was performed by membrane staining. Cell cycle distribution and RNA content were assessed by flow cytometry and senescence was assessed via Ξ²-galactosidase staining. We demonstrated that irradiated CICs survived and retained their self-renewal capacity for at least four generations. We show that fractionated radiation not only spared CICs but also mobilized them from a quiescent/G0 phase of the cell cycle into actively cycling cells, while the surviving non-tumorigenic cells were driven into senescence. The breast CIC population retains increased self-renewal capacity over several generations and therefore, we conclude that increases in the number of CICs after sublethal doses of radiation have potential clinical importance. Prevention of this process may lead to improved clinical outcome.
         datePublished:2010-02-16T00:00:00Z
         dateModified:2010-02-16T00:00:00Z
         pageStart:1
         pageEnd:13
         license:http://creativecommons.org/licenses/by/2.0/
         sameAs:https://doi.org/10.1186/bcr2479
         keywords:
            T47D Cell
            Proteasome Activity
            Breast Cancer Stem Cell
            T47D Cell Line
            T47D Breast Cancer Cell
            Cancer Research
            Oncology
            Surgical Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2479/MediaObjects/13058_2009_2443_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2479/MediaObjects/13058_2009_2443_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2479/MediaObjects/13058_2009_2443_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2479/MediaObjects/13058_2009_2443_Fig4_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2479/MediaObjects/13058_2009_2443_Fig5_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2479/MediaObjects/13058_2009_2443_Fig6_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2479/MediaObjects/13058_2009_2443_Fig7_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2479/MediaObjects/13058_2009_2443_Fig8_HTML.jpg
         isPartOf:
            name:Breast Cancer Research
            issn:
               1465-542X
            volumeNumber:12
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Chann Lagadec
               affiliation:
                     name:David Geffen School of Medicine at University of California, Los Angeles
                     address:
                        name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Erina Vlashi
               affiliation:
                     name:David Geffen School of Medicine at University of California, Los Angeles
                     address:
                        name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lorenza Della Donna
               affiliation:
                     name:David Geffen School of Medicine at University of California, Los Angeles
                     address:
                        name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:YongHong Meng
               affiliation:
                     name:David Geffen School of Medicine at University of California, Los Angeles
                     address:
                        name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Carmen Dekmezian
               affiliation:
                     name:David Geffen School of Medicine at University of California, Los Angeles
                     address:
                        name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kwanghee Kim
               affiliation:
                     name:David Geffen School of Medicine at University of California, Los Angeles
                     address:
                        name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Frank Pajonk
               affiliation:
                     name:University of California, Los Angeles
                     address:
                        name:Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment
      description:Recent data indicate a hierarchical organization of many solid cancers, including breast cancer, with a small number of cancer initiating cells (CICs) that have the ability to self-renew and exhibit multi-lineage potency. We, and others, have demonstrated that CICs in breast cancer and glioma are relatively resistant to ionizing radiation if compared to their non-tumorigenic counterparts. However, the extent of the remaining self-renewing capacity of CICs after fractions of radiation is currently unknown. We hypothesized that CICs, in contrast to their non-tumorigenic counterparts, not only survive fractions of ionizing radiation but also retain the CIC phenotype as defined by operational means. We used two marker systems to identify breast CICs (CD24-/low/CD44high, or lack of proteasome activity) and performed sphere-forming assays after multiple clinical fractions of radiation. Lineage tracking was performed by membrane staining. Cell cycle distribution and RNA content were assessed by flow cytometry and senescence was assessed via Ξ²-galactosidase staining. We demonstrated that irradiated CICs survived and retained their self-renewal capacity for at least four generations. We show that fractionated radiation not only spared CICs but also mobilized them from a quiescent/G0 phase of the cell cycle into actively cycling cells, while the surviving non-tumorigenic cells were driven into senescence. The breast CIC population retains increased self-renewal capacity over several generations and therefore, we conclude that increases in the number of CICs after sublethal doses of radiation have potential clinical importance. Prevention of this process may lead to improved clinical outcome.
      datePublished:2010-02-16T00:00:00Z
      dateModified:2010-02-16T00:00:00Z
      pageStart:1
      pageEnd:13
      license:http://creativecommons.org/licenses/by/2.0/
      sameAs:https://doi.org/10.1186/bcr2479
      keywords:
         T47D Cell
         Proteasome Activity
         Breast Cancer Stem Cell
         T47D Cell Line
         T47D Breast Cancer Cell
         Cancer Research
         Oncology
         Surgical Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2479/MediaObjects/13058_2009_2443_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2479/MediaObjects/13058_2009_2443_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2479/MediaObjects/13058_2009_2443_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2479/MediaObjects/13058_2009_2443_Fig4_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2479/MediaObjects/13058_2009_2443_Fig5_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2479/MediaObjects/13058_2009_2443_Fig6_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2479/MediaObjects/13058_2009_2443_Fig7_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2479/MediaObjects/13058_2009_2443_Fig8_HTML.jpg
      isPartOf:
         name:Breast Cancer Research
         issn:
            1465-542X
         volumeNumber:12
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Chann Lagadec
            affiliation:
                  name:David Geffen School of Medicine at University of California, Los Angeles
                  address:
                     name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Erina Vlashi
            affiliation:
                  name:David Geffen School of Medicine at University of California, Los Angeles
                  address:
                     name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lorenza Della Donna
            affiliation:
                  name:David Geffen School of Medicine at University of California, Los Angeles
                  address:
                     name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:YongHong Meng
            affiliation:
                  name:David Geffen School of Medicine at University of California, Los Angeles
                  address:
                     name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Carmen Dekmezian
            affiliation:
                  name:David Geffen School of Medicine at University of California, Los Angeles
                  address:
                     name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kwanghee Kim
            affiliation:
                  name:David Geffen School of Medicine at University of California, Los Angeles
                  address:
                     name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Frank Pajonk
            affiliation:
                  name:University of California, Los Angeles
                  address:
                     name:Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research
      issn:
         1465-542X
      volumeNumber:12
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:David Geffen School of Medicine at University of California, Los Angeles
      address:
         name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
         type:PostalAddress
      name:David Geffen School of Medicine at University of California, Los Angeles
      address:
         name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
         type:PostalAddress
      name:David Geffen School of Medicine at University of California, Los Angeles
      address:
         name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
         type:PostalAddress
      name:David Geffen School of Medicine at University of California, Los Angeles
      address:
         name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
         type:PostalAddress
      name:David Geffen School of Medicine at University of California, Los Angeles
      address:
         name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
         type:PostalAddress
      name:David Geffen School of Medicine at University of California, Los Angeles
      address:
         name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
         type:PostalAddress
      name:University of California, Los Angeles
      address:
         name:Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Chann Lagadec
      affiliation:
            name:David Geffen School of Medicine at University of California, Los Angeles
            address:
               name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
               type:PostalAddress
            type:Organization
      name:Erina Vlashi
      affiliation:
            name:David Geffen School of Medicine at University of California, Los Angeles
            address:
               name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
               type:PostalAddress
            type:Organization
      name:Lorenza Della Donna
      affiliation:
            name:David Geffen School of Medicine at University of California, Los Angeles
            address:
               name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
               type:PostalAddress
            type:Organization
      name:YongHong Meng
      affiliation:
            name:David Geffen School of Medicine at University of California, Los Angeles
            address:
               name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
               type:PostalAddress
            type:Organization
      name:Carmen Dekmezian
      affiliation:
            name:David Geffen School of Medicine at University of California, Los Angeles
            address:
               name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
               type:PostalAddress
            type:Organization
      name:Kwanghee Kim
      affiliation:
            name:David Geffen School of Medicine at University of California, Los Angeles
            address:
               name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
               type:PostalAddress
            type:Organization
      name:Frank Pajonk
      affiliation:
            name:University of California, Los Angeles
            address:
               name:Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
      name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
      name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
      name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
      name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
      name:Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
      name:Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, USA

External Links {πŸ”—}(124)

Analytics and Tracking {πŸ“Š}

  • Google Tag Manager

Libraries {πŸ“š}

  • Clipboard.js
  • Prism.js

CDN Services {πŸ“¦}

  • Crossref

6.07s.